
PASSAGE BIO (PASG) Stock Forecast & Price Target
PASSAGE BIO (PASG) Analyst Ratings
Bulls say
Passage Bio is at a crucial stage in their development, with recent safety concerns for their lead programs FTD-GRN and FTD-C9orf72. However, the company has responded appropriately with protocol amendments and is continuing to enroll and dose patients, showing a commitment to their pipeline. The company also has a cash balance of $46.3M and expects it to last into 2027. While the current price target may seem low at $23, the potential upside is significant as the company releases updated biomarker data in the first half of 2026 and receives regulatory feedback on a pivotal trial design later this year.
Bears say
Passage Bio is currently a clinical-stage company, with a single reportable segment focused on gene therapies for neurodegenerative diseases. Their financial outlook is based on a peak revenue analysis with multiple assumptions, and their model assumes dilution in 2026 and 2027. The company is subject to the standard risks of the biotech industry, as well as specific risks such as competition in some indications, manufacturing capacity constraints, and potential delays due to the novelty and complexity of their gene therapy products. Additionally, their lead program PBFT02 faces competition from other companies, and any setbacks in clinical development or unforeseen safety issues could significantly impact their outlook and financial performance.
This aggregate rating is based on analysts' research of PASSAGE BIO and is not a guaranteed prediction by Public.com or investment advice.
PASSAGE BIO (PASG) Analyst Forecast & Price Prediction
Start investing in PASSAGE BIO (PASG)
Order type
Buy in
Order amount
Est. shares
0 shares